Joan Bladé

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Antonio Palumbo, Roman Hájek, Michel Delforge et al. · New England Journal of Medicine · 2012 · 739 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome

Jesús F. San Miguel, Júlia Almeida, Gema Mateo et al. · Blood · 2002 · 159 citations · Full text

Medicine, Hematology, Immunology +16

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition

Miquel Granell, Xavier Calvo, Antoni García‐Guiñón et al. · Haematologica · 2017 · 128 citations · Full text

Medicine, Hematology, Oncology +12

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12